Mr. Speaker, the New Democratic Party caucus also has concerns with regard to this legislation, specifically in the areas she addressed, and that is the safety of drugs and the shortcuts that can be taken in clinical trials.
I remind everyone that some years back the Liberals closed Health Canada drug labs and entered into what they called partnerships between drugs companies and Health Canada. That activity has compelled the NDP to take a very close look because it would seem to compromise the safety of some products.
Could the member opposite comment on that? Does she see a need to return to a more rigorous Health Canada review?